Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS(ON) Cancer Drug Development
The Pharma Data
JUNE 24, 2025
The partnership represents a major financial and strategic milestone for Revolution Medicines, which has built a robust pipeline of targeted therapies aimed at cancers driven by mutations in the RAS family of genes—some of the most prevalent and historically difficult-to-drug oncogenes in human cancer.
Let's personalize your content